Description

APVO425 is a humanized, bispecific ADAPTIR™ molecule targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and CD3. ROR1 is a tumor-specific antigen that is upregulated in many B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, and solid malignancies, including prostate cancer, ovarian cancer, renal cell carcinoma, non-small cell lung cancer, triple negative breast cancer (TNBC), and pancreatic cancer.

APVO425’s mechanism of action is to redirect T cells to kill ROR1-expressing tumor cells.